Eric Nolen-Doerr1, Mary-Catherine Stockman2, Ivania Rizo3. 1. Section of Endocrinology, Diabetes, Nutrition, and Weight Management, Boston University School of Medicine and Boston Medical Center, 720 Harrison Avenue, Doctor's Office Building, Suite 8100, Boston, MA, 02118, USA. Eric.Nolen-Doerr@bmc.org. 2. Section of Endocrinology, Diabetes, Nutrition, and Weight Management, Boston University School of Medicine and Boston Medical Center, 720 Harrison Avenue, Doctor's Office Building, Suite 8100, Boston, MA, 02118, USA. Mary-Catherine.Stockman@bmc.org. 3. Section of Endocrinology, Diabetes, Nutrition, and Weight Management, Boston University School of Medicine and Boston Medical Center, 720 Harrison Avenue, Doctor's Office Building, Suite 8100, Boston, MA, 02118, USA. Ivania.Rizo@bmc.org.
Abstract
PURPOSE OF REVIEW: The purpose of this review is to emphasize the pivotal role of glucagon-like peptide 1 (GLP-1) in tackling the parallel epidemics of obesity and type 2 diabetes (T2DM). RECENT FINDINGS: GLP-1-based therapies and in particular GLP-1 receptor agonists (GLP-1 RA) have proven to be effective in lowering blood glucose and decreasing weight. GLP-1 RA not only mitigate these significant medical burdens but also result in weight loss and weight loss independent factors that decrease cardiovascular disease (CVD) and microvascular complications of T2DM, such as diabetic nephropathy. GLP-1-based therapies are critical for a patient-centered approach in choosing appropriate pharmacotherapy for T2DM and obesity while also taking into consideration comorbidities, such as cardiovascular and chronic kidney diseases.
PURPOSE OF REVIEW: The purpose of this review is to emphasize the pivotal role of glucagon-like peptide 1 (GLP-1) in tackling the parallel epidemics of obesity and type 2 diabetes (T2DM). RECENT FINDINGS:GLP-1-based therapies and in particular GLP-1 receptor agonists (GLP-1RA) have proven to be effective in lowering blood glucose and decreasing weight. GLP-1RA not only mitigate these significant medical burdens but also result in weight loss and weight loss independent factors that decrease cardiovascular disease (CVD) and microvascular complications of T2DM, such as diabetic nephropathy. GLP-1-based therapies are critical for a patient-centered approach in choosing appropriate pharmacotherapy for T2DM and obesity while also taking into consideration comorbidities, such as cardiovascular and chronic kidney diseases.
Entities:
Keywords:
Cardiovascular disease; Glucagon-like peptide-1; Incretin; Obesity; Type 2 diabetes; Weight loss
Authors: Teresa Caro-Ordieres; Gema Marín-Royo; Lucas Opazo-Ríos; Luna Jiménez-Castilla; Juan Antonio Moreno; Carmen Gómez-Guerrero; Jesús Egido Journal: J Clin Med Date: 2020-01-27 Impact factor: 4.241
Authors: Matthew C Riddle; Hertzel C Gerstein; Denis Xavier; William C Cushman; Lawrence A Leiter; Peter J Raubenheimer; Charles M Atisso; Sohini Raha; Oralee J Varnado; Manige Konig; Mark Lakshmanan; Edward Franek Journal: J Clin Endocrinol Metab Date: 2021-04-23 Impact factor: 5.958
Authors: P Marzullo; T Daffara; C Mele; M Zavattaro; A Ferrero; M Caputo; F Prodam; G Aimaretti Journal: J Endocrinol Invest Date: 2022-04-16 Impact factor: 5.467